Home › Research › TREM2 and immune genetics
Exploring the Impact of TREM2 in Tumor-Associated Macrophages
Khantakova D, Brioschi S, Molgora M.. Vaccines, 2022-06-14
Topic: Brain proteins, microglia and lab models
Plain-language summary
Tumor-associated macrophages (TAMs) represent a key component of the tumor microenvironment and are generally associated with immunosuppression and poor prognosis. TREM2 is a transmembrane receptor of the immunoglobulin superfamily expressed in myeloid cells. TREM2 has been extensively studied in microglia and neurodegenerative diseases and recently emerged as a marker of pro-tumorigenic macrophages.
What this study adds
Evidence grade: Low
This is a narrative review. This review discusses TREM2 as a marker of pro-tumorigenic macrophages in cancer, where blocking TREM2 improved tumor control in models. It is about cancer, not Alzheimer's disease, and does not show a treatment or cure for Alzheimer's.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Khantakova, D., Brioschi, S., & Molgora, M. (2022). Exploring the Impact of TREM2 in Tumor-Associated Macrophages. Vaccines. https://doi.org/10.3390/vaccines10060943
Vancouver
Khantakova D, Brioschi S, Molgora M. Exploring the Impact of TREM2 in Tumor-Associated Macrophages. Vaccines. 2022. doi:10.3390/vaccines10060943. PMID: 35746551.
BibTeX
@article{khantakova2022-35746551,
author = {Khantakova, D. and Brioschi, S. and Molgora, M.},
title = {{Exploring the Impact of TREM2 in Tumor-Associated Macrophages}},
journal = {Vaccines},
year = {2022},
doi = {10.3390/vaccines10060943},
pmid = {35746551},
url = {https://doi.org/10.3390/vaccines10060943}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- TREM2 is a transmembrane receptor of the immunoglobulin superfamily expressed in myeloid cells.
- TREM2 has been extensively studied in microglia and neurodegenerative diseases and recently emerged as a marker of pro-tumorigenic macrophages.
- The accumulation of TREM2-expressing TAMs was reported across numerous cancer patients and tumor models.
- TREM2 genetic blockade or TREM2 targeting with antibodies resulted in improved tumor control, enhanced response to anti-PD1, and significant changes in the tumor immune landscape.
Why it matters
This review discusses TREM2 as a marker of pro-tumorigenic macrophages in cancer, where blocking TREM2 improved tumor control in models. It is about cancer, not Alzheimer's disease, and does not show a treatment or cure for Alzheimer's.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 44/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Vaccines) |
| Journal's citation record | 1 / 4 | Vaccines: journal h-index 132 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 58 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 9.7 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 3 / 6 | Cited 3.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 2 / 4 | Cited 47 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Martina Molgora: h-index 24 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35746551) |
| Free to read | 2 / 2 | Free to read |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 50.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in TREM2 and immune genetics from nearby years
Also tagged “r47h”
363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.